NR AWPL
AU Ugnon-Cafe,S.; Bilheude,J.M.; Sauvage,N.; Streichenberger,N.; Krolak-Salmon,P.; Quadrio,I.; Perret Liaudet,A.
TI Feasability before evaluation of TeSeeTM CJD ELISA and TeSeeTM Western Blot for Creutzfeldt-Jakob disease (CJD) diagnostic
QU International Conference - Prion 2006: Strategies, advances and trends towards protection of society - 3.10.-6.10.2006, Torino, Italy, Lingotto Conference Centre - Poster sessions DIA-58
PT Konferenz-Poster
AB Since 1997, we have been using in our lab a sensitive Western-Blot assay with ultracentrifugation step for diagnosis purpose. However, this assay is time consuming and needs some experience for recovering of ultracentrifugation pellet. The Bio-Rad TeSeE CJD ELISA test (TeSeE Elisa) is an improved version of the already existing TeSeE screening test commercialized for the detection of the Transmissible Spongiform Encephalopathies (TSE) in brain or peripheral tissues of animals. The BioRad TeSeE WESTERN-BLOT assay (TeSeE WB) is routinely used for the confirmation of TSE suspected animals. Our goal is to implement rapid and robust tools for a routine CJD diagnostic, at least as sensitive and specific than our current protocol and/or reported protocols. The aim of this work was to test the ability of TeSeE ELISA and TeSeE WB for detecting the PrPres in CJD patients. For brain detection of PrPres, samples were obtained from 28 patients: 14 non-CJD, 13 CJD and 1 Fatal Familial Insomnia (FFI). For peripheral tissues, 8 patients were selected: 3 vCJD, 2 sCJD, 1 mutation CJD and 2 non-CJD patients. Initial screening was done with the TeSeE Elisa. Then, the confirmation of all suspected cases (repeatedly positive at screening) was done with the TeSeE WB. The TeSeE Elisa and TeSeE WB were able to detect a significant signal of PrPres in the brain of all patients with 100% specificity and 100% sensitivity. The same results were observed with the two assays when testing 8 spleens and 2 tonsils. The TeSeE WB has detected the typical molecular pattern of the PrPres in brain, tonsil and spleen in the 2 v-CJD patients and has distinguished between PrPres types 1 and 2. The performances (analytical sensitivity, precision) of the two assays were also evaluated during this study. This feasibility study has demonstrated the adaptability of TeSeE Elisa and TeSeE WB to detect PrPres in human brain, spleen or tonsil. They seem to be a correct alternative to the time consuming method with ultracentrifugation. Furthermore, to consolidate these preliminary results, a complete study will be needed on a larger cohort of patients.
AD S. Ugnon-Café, N. Streichenberger, P. Krolak-Salmon, A. Perret Liaudet: Prion Diseases Diagnosis Lab., Neurological Hospital, Lyon, France; J.M. Bilheude, N. Sauvage: Bio-Rad R&D, Marnes-la-Coquette, France
SP englisch
PO Italien